Drug Therapy
Development

AP-001
A New Era in Cancer Treatment

Our Therapeutics

Avenzoar specializes in developing small molecule therapeutics for cancer. Our lead drug, AP-001 (Metavert™), is a dual inhibitor small molecule designed to prevent cancer growth and metastasis. AP-001 has the potential to revolutionize cancer therapy.

Pre-Clinical Results | Trials

AP-001 is an innovative anti-cancer drug that targets two pro-cancer pathways simultaneously. Pre-clinical results show significant prevention of pancreatic cancer growth and metastasis with no significant toxicity. Clinical trials for pancreatic cancer patients are set to begin in 2025, with potential trials for ovarian and metastatic liver cancer to follow.

Pancreatic Cancer

Survival rates for pancreatic cancer are notably low, with only 12% of patients surviving beyond five years post-diagnosis, largely due  to late-stage diagnoses. Surgical removal of tumors is feasible in less than 20% of cases.

Current treatments primarily involve chemotherapy and radiation therapy, aiming to control the disease and improve patient quality of life.
0 th Most Prevalent
Cancer Globally
0 New Cases

Annually

0 Deaths

Each Year

0 New Cases
0 Deaths Annually
0 th Most Diagnosed

in the U.S.

Tumor Removal

Less Than 20%

Ovarian Cancer

Five-year ovarian cancer survival rates vary between countries. For example, in more developed countries, current rates range from 36% to 46%. However, in some countries, the figure is much lower.
The five-year survival rate is 51%, falling well below that for other cancers.
The first-line treatment for ovarian cancer typically includes surgery, followed by chemotherapy with platinum-based agents and a taxane.

0 th Most Common Cancer Among Women Globally
Female Icon
0 New Cases

Annually

0 Deaths

Each Year

0 New Cases
0 Deaths Annually
Micro_Survival_OvarianV2

51% Five-Year

Survival Rate

Source: World Ovarian Cancer Coalition

Promising Advancements
in Pancreatic Cancer Treatment

Avenzoar’s leading investigational drug, AP-001, represents a promising advancement in pancreatic cancer treatment. Through rigorous preclinical studies, AP-001 has shown potential in inhibiting metastasis and overcoming chemo-resistance mechanisms, critical challenges in treating pancreatic cancer. As Avenzoar prepares for clinical trials in 2025, our focus on developing breakthrough therapies underscores a commitment to improving patient outcomes and transforming cancer care. 

In summary, pancreatic cancer poses a significant public health challenge worldwide, characterized by high mortality rates, limited treatment options, and a pressing need for continued research and clinical advancements to improve patient outcomes.

Potential Impact

of AP-001 on Pancreatic Cancer

Dr. Stephen Pandol
Director of Basic and Translational
Pancreas Research at Cedars-Sinai Medical Center

Interested in learning more about AP-001?

Get in touch with us today
Scroll to Top